Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apollomics Inc. filings document foreign issuer current reports, oncology program updates, financing transactions, governance changes, and liquidity-related disclosures. The company furnishes Form 6-K reports and references Form 20-F reporting status, with exhibits covering financial results, clinical updates for vebreltinib, and corporate developments affecting ongoing operations.
The filing record also covers material agreements, related-party convertible note financing, PIPE share issuance, resale registration obligations, board and committee appointments, proxy materials, and risk disclosures tied to cash resources, collaboration payments, Nasdaq listing compliance, and the company’s capital structure as a Cayman Islands issuer with Class A ordinary shares and warrants.
Apollomics Inc. received additional funding support from its chairman and CEO, Hung‑Wen (Howard) Chen, who, together with his wholly owned entity King Regent Management Limited, beneficially owns 901,362 Class A ordinary shares, representing 41.8% of the class.
On March 30, 2026, the company issued a $2,000,000 Convertible Promissory Note to Mr. Chen as an unsecured bridge loan. The principal will automatically convert into Apollomics equity in the next equity financing that raises at least $10,000,000, at a conversion price equal to 80% of the lowest per‑share purchase price in that financing. If no such financing occurs by the eighteen‑month maturity, Mr. Chen may elect to convert the note into Class A ordinary shares based on the average closing price over the ten trading days before maturity.
Mr. Chen holds 138,334 Class A ordinary shares directly, and King Regent holds 763,028 shares. In addition, on March 15, 2026, 5,000 restricted stock units granted to Mr. Chen vested, each representing the right to receive one Class A ordinary share.
Apollomics Inc. received additional funding support from its chairman and CEO, Hung‑Wen (Howard) Chen, who, together with his wholly owned entity King Regent Management Limited, beneficially owns 901,362 Class A ordinary shares, representing 41.8% of the class.
On March 30, 2026, the company issued a $2,000,000 Convertible Promissory Note to Mr. Chen as an unsecured bridge loan. The principal will automatically convert into Apollomics equity in the next equity financing that raises at least $10,000,000, at a conversion price equal to 80% of the lowest per‑share purchase price in that financing. If no such financing occurs by the eighteen‑month maturity, Mr. Chen may elect to convert the note into Class A ordinary shares based on the average closing price over the ten trading days before maturity.
Mr. Chen holds 138,334 Class A ordinary shares directly, and King Regent holds 763,028 shares. In addition, on March 15, 2026, 5,000 restricted stock units granted to Mr. Chen vested, each representing the right to receive one Class A ordinary share.
Apollomics Inc. entered into a $2,000,000 unsecured Convertible Promissory Note with its Chairman and CEO, Hung-Wen (Howard) Chen, providing short-term bridge financing. The Note carries a 0% interest rate and is intended to supply working capital for clinical development programs and general corporate operations.
The principal will automatically convert into Apollomics equity upon a future equity financing that raises at least $10,000,000, at a conversion price set at 80% of the lowest per-share price paid by new investors. If no such financing occurs before the 18‑month maturity, Mr. Chen may elect to convert based on the 10‑day average closing price. As a related-party transaction, it was reviewed by the independent Audit Committee and approved by the Board, with Mr. Chen abstaining.
Apollomics Inc. entered into a $2,000,000 unsecured Convertible Promissory Note with its Chairman and CEO, Hung-Wen (Howard) Chen, providing short-term bridge financing. The Note carries a 0% interest rate and is intended to supply working capital for clinical development programs and general corporate operations.
The principal will automatically convert into Apollomics equity upon a future equity financing that raises at least $10,000,000, at a conversion price set at 80% of the lowest per-share price paid by new investors. If no such financing occurs before the 18‑month maturity, Mr. Chen may elect to convert based on the 10‑day average closing price. As a related-party transaction, it was reviewed by the independent Audit Committee and approved by the Board, with Mr. Chen abstaining.
Apollomics Inc. director and CEO Chen Hung-Wen reported his initial holdings. He holds 20,000 restricted stock units, each representing one Class A Ordinary Share. The RSUs vested for 5,000 shares on February 9, 2026, with 5,000 more vesting on each of March 15, 2026, June 15, 2026 and September 15, 2026. He also directly holds 133,334 Class A Ordinary Shares and indirectly 763,028 shares through King Regent Management Limited, over which he has voting and dispositive power while disclaiming beneficial ownership beyond his pecuniary interest.
Apollomics Inc. director and CEO Chen Hung-Wen reported his initial holdings. He holds 20,000 restricted stock units, each representing one Class A Ordinary Share. The RSUs vested for 5,000 shares on February 9, 2026, with 5,000 more vesting on each of March 15, 2026, June 15, 2026 and September 15, 2026. He also directly holds 133,334 Class A Ordinary Shares and indirectly 763,028 shares through King Regent Management Limited, over which he has voting and dispositive power while disclaiming beneficial ownership beyond his pecuniary interest.
Apollomics Inc. director Hong-Jung Chen filed an initial ownership report detailing equity and derivative holdings in the company. Chen directly holds 2,120 Class A Ordinary Shares. In addition, Chen has restricted stock units representing 2,000 Class A Ordinary Shares, with 500 units vested on February 9, 2026 and 500 more vesting on each of March 15, June 15 and September 15, 2026, subject to continued service.
Chen also holds stock options over 2,290 Class A Ordinary Shares at an exercise price of $75.00 per share, which are fully vested following a 1-for-100 reverse stock split adjustment. A second option grant covers 2,028 Class A Ordinary Shares at an exercise price of $6.20 per share and will vest in full on March 31, 2026, subject to continued service. The filing further discloses warrants linked to 304 Class A Ordinary Shares, reflecting an adjusted exercise price of $1,150.00 per full share, as each warrant is exercisable for 0.01 Class A Ordinary Share at $11.50 per warrant.
Apollomics Inc. director Hong-Jung Chen filed an initial ownership report detailing equity and derivative holdings in the company. Chen directly holds 2,120 Class A Ordinary Shares. In addition, Chen has restricted stock units representing 2,000 Class A Ordinary Shares, with 500 units vested on February 9, 2026 and 500 more vesting on each of March 15, June 15 and September 15, 2026, subject to continued service.
Chen also holds stock options over 2,290 Class A Ordinary Shares at an exercise price of $75.00 per share, which are fully vested following a 1-for-100 reverse stock split adjustment. A second option grant covers 2,028 Class A Ordinary Shares at an exercise price of $6.20 per share and will vest in full on March 31, 2026, subject to continued service. The filing further discloses warrants linked to 304 Class A Ordinary Shares, reflecting an adjusted exercise price of $1,150.00 per full share, as each warrant is exercisable for 0.01 Class A Ordinary Share at $11.50 per warrant.
Apollomics Inc. director Huang Ya-Chi filed an initial ownership report showing a holding of restricted stock units tied to the company’s Class A Ordinary Shares. The filing reflects 2,000 restricted stock units, vesting in four installments of 500 shares each during 2026. Each unit represents the right to receive one Class A Ordinary Share.
Apollomics Inc. director Huang Ya-Chi filed an initial ownership report showing a holding of restricted stock units tied to the company’s Class A Ordinary Shares. The filing reflects 2,000 restricted stock units, vesting in four installments of 500 shares each during 2026. Each unit represents the right to receive one Class A Ordinary Share.
Apollomics Inc. director TSAI HSIEN-SHU reported an initial holding of restricted stock units that are linked to the company’s Class A Ordinary Shares. The position covers restricted stock units tied to 2,000 underlying Class A Ordinary Shares held directly.
According to the footnotes, these restricted stock units vested with respect to 500 shares upon grant on February 9, 2026, with an additional 500 shares scheduled to vest on each of March 15, 2026, June 15, 2026 and September 15, 2026. Each unit represents a contingent right to receive one Class A Ordinary Share.
Apollomics Inc. director TSAI HSIEN-SHU reported an initial holding of restricted stock units that are linked to the company’s Class A Ordinary Shares. The position covers restricted stock units tied to 2,000 underlying Class A Ordinary Shares held directly.
According to the footnotes, these restricted stock units vested with respect to 500 shares upon grant on February 9, 2026, with an additional 500 shares scheduled to vest on each of March 15, 2026, June 15, 2026 and September 15, 2026. Each unit represents a contingent right to receive one Class A Ordinary Share.
Apollomics Inc. director Jan Chen-Huan reported initial beneficial ownership of 2,000 Restricted Stock Units (RSUs), each tied to one Class A Ordinary Share. The RSUs vested with respect to 500 shares on February 9, 2026, with additional 500-share tranches scheduled on March 15, 2026, June 15, 2026 and September 15, 2026. Each RSU represents a contingent right to receive one Class A Ordinary Share, and the position is held directly.
Apollomics Inc. director Jan Chen-Huan reported initial beneficial ownership of 2,000 Restricted Stock Units (RSUs), each tied to one Class A Ordinary Share. The RSUs vested with respect to 500 shares on February 9, 2026, with additional 500-share tranches scheduled on March 15, 2026, June 15, 2026 and September 15, 2026. Each RSU represents a contingent right to receive one Class A Ordinary Share, and the position is held directly.
Apollomics Inc. director and COO Chen Yi-Kuei filed an initial Form 3 reporting his equity holdings. He directly holds restricted stock units covering 20,000 Class A Ordinary Shares, vesting in four installments of 5,000 shares each during 2026. Each unit represents the right to receive one share. Through Maxpro Investment Co., Ltd., he is attributed 101,248 Class A Ordinary Shares and warrants exercisable for 3,823 Class A Ordinary Shares at an adjusted exercise price of $1,150.00 per full share, or $11.50 per warrant. He disclaims beneficial ownership of the Maxpro-held securities except to the extent of his pecuniary interest.
Apollomics Inc. director and COO Chen Yi-Kuei filed an initial Form 3 reporting his equity holdings. He directly holds restricted stock units covering 20,000 Class A Ordinary Shares, vesting in four installments of 5,000 shares each during 2026. Each unit represents the right to receive one share. Through Maxpro Investment Co., Ltd., he is attributed 101,248 Class A Ordinary Shares and warrants exercisable for 3,823 Class A Ordinary Shares at an adjusted exercise price of $1,150.00 per full share, or $11.50 per warrant. He disclaims beneficial ownership of the Maxpro-held securities except to the extent of his pecuniary interest.
Apollomics Inc. disclosed initial holdings for Chief Financial Officer Lin Peter Kuan-How, showing 40,000 Restricted Stock Units tied to Class A Ordinary Shares. The RSUs vest in stages: 10,000 shares vested upon grant on February 9, 2026, with an additional 10,000 vesting on each of March 15, 2026, June 15, 2026 and September 15, 2026. Each RSU represents a contingent right to receive one Class A Ordinary Share, and the position is reported as directly owned.
Apollomics Inc. disclosed initial holdings for Chief Financial Officer Lin Peter Kuan-How, showing 40,000 Restricted Stock Units tied to Class A Ordinary Shares. The RSUs vest in stages: 10,000 shares vested upon grant on February 9, 2026, with an additional 10,000 vesting on each of March 15, 2026, June 15, 2026 and September 15, 2026. Each RSU represents a contingent right to receive one Class A Ordinary Share, and the position is reported as directly owned.
Apollomics Inc. disclosed on a Schedule 13D that Hung-Wen (Howard) Chen and his wholly owned vehicle, King Regent Management Limited, together hold 896,362 Class A ordinary shares, representing 41.8% of the issuer's outstanding Class A shares (2,146,151 shares outstanding as disclosed). The holdings comprise 133,334 shares directly held by Mr. Chen and 763,028 shares held by King Regent. The filing amends a prior Schedule 13G and notes that Mr. Chen is Chairman and CEO; King Regent is a private investment holding company wholly owned by him. The transaction source is identified as PIPE subscription agreements executed on September 2, 2025, and the filing includes a joint filing agreement as an exhibit.